Our Pricing

Aciclovir 400mg vs Valaciclovir: Clinical Comparison for Cold Sore Treatment

When comparing aciclovir 400mg vs valaciclovir UK options, both antiviral medications effectively suppress herpes simplex virus replication, but they differ in dosing frequency and bioavailability. At Cured Pharmacy, we dispense both treatments following clinical assessment by UK prescribers, with aciclovir cold sore treatment starting from £4.49.

How Aciclovir and Valaciclovir Work Against Herpes Simplex Virus

Aciclovir is a nucleoside analogue antiviral that interferes with viral DNA polymerase, preventing herpes simplex virus (HSV) replication in infected cells [1]. When you take aciclovir orally, approximately 15-30% is absorbed through the gastrointestinal tract, which is why multiple daily doses are required to maintain therapeutic blood levels.

Valaciclovir is the L-valine ester prodrug of aciclovir, meaning it converts to aciclovir in the body after absorption [2]. The key clinical advantage is significantly improved bioavailability—approximately 54% compared to aciclovir's 15-30%—allowing less frequent dosing whilst achieving similar or superior antiviral effects [2]. Both medications are licensed by the MHRA for treatment and suppression of recurrent herpes simplex infections.

Once converted to its active triphosphate form inside infected cells, aciclovir (whether taken directly or via valaciclovir) selectively inhibits viral DNA synthesis without significantly affecting normal cellular processes [1]. This selectivity explains why both medications are generally well-tolerated with minimal systemic side effects when used at recommended doses.

Aciclovir 400mg vs Valaciclovir: Dosing and Convenience

For episodic treatment of recurrent cold sores, aciclovir 400mg is typically prescribed five times daily for five days, whilst valaciclovir requires only two doses daily for the same duration [3]. This difference stems directly from the bioavailability gap—valaciclovir's superior absorption means fewer doses achieve comparable antiviral activity.

In clinical practice, dosing frequency significantly impacts treatment adherence. Patients prescribed five-times-daily aciclovir may miss doses due to work schedules, sleep patterns, or simply forgetting mid-day tablets. Valaciclovir's twice-daily regimen (morning and evening) fits more naturally into daily routines, potentially improving compliance and clinical outcomes.

For suppressive therapy in patients with frequent recurrences (six or more episodes annually), aciclovir is typically prescribed as 400mg twice daily, whilst valaciclovir suppression uses 500mg once daily [3]. Both regimens have demonstrated efficacy in reducing recurrence frequency by approximately 70-80% in clinical trials, though individual response varies [4].

Starting Treatment Early: The Prodrome Window

Both aciclovir and valaciclovir work most effectively when started during the prodromal phase—the tingling, itching, or burning sensation that precedes visible cold sore lesions by 6-24 hours [4]. Starting treatment after lesions have fully developed reduces the potential benefit, though some symptom reduction may still occur. Patients who experience frequent recurrences often keep a supply at home to initiate treatment immediately when prodromal symptoms appear, subject to prescriber approval for such use.

Clinical Efficacy: Which Medication Works Better?

Head-to-head trials comparing aciclovir and valaciclovir for herpes labialis (cold sores) show comparable clinical outcomes when patients adhere to prescribed regimens [3]. A systematic review of antiviral treatments for recurrent herpes simplex infections found that both medications reduce lesion healing time by approximately 1-2 days compared to placebo, with no statistically significant difference between the two antivirals when comparing compliant patients [4].

The practical difference emerges in real-world adherence rather than pharmacological efficacy. Studies examining medication compliance show that simpler dosing regimens (once or twice daily) achieve approximately 20-30% better adherence than regimens requiring five daily doses [5]. This adherence advantage may translate to marginally better real-world outcomes for valaciclovir, though the medications are biochemically equivalent once aciclovir reaches therapeutic levels.

For immunocompromised patients or those with severe recurrent infections, some UK specialists prefer valaciclovir due to its more predictable pharmacokinetics and reduced risk of subtherapeutic dosing from missed tablets [2]. However, both medications are considered first-line treatments by NICE guidance, and the choice often depends on patient preference, cost considerations, and prescriber experience.

Resistance and Treatment Failure

Aciclovir resistance remains rare in immunocompetent patients, occurring in less than 1% of cases, though rates increase to 5-10% in immunocompromised individuals receiving long-term suppressive therapy [1]. Because valaciclovir converts to aciclovir, resistance to one medication confers resistance to the other—they are not alternatives if treatment failure occurs. In confirmed resistance cases, UK prescribers may consider alternative antivirals such as foscarnet, though this is typically managed in specialist settings.

Side Effects and Safety Considerations

Both aciclovir and valaciclovir share similar safety profiles, as valaciclovir converts to aciclovir after absorption [2]. The most commonly reported side effects include headache (affecting approximately 13-35% of patients in clinical trials), nausea (4-15%), and abdominal discomfort (2-8%) [3]. These effects are generally mild and resolve without requiring treatment discontinuation.

Renal function requires consideration with both medications, as aciclovir is primarily eliminated through the kidneys. Patients with estimated glomerular filtration rate (eGFR) below 50 mL/min require dose adjustments to prevent accumulation, which can rarely cause neurological side effects such as confusion, hallucinations, or tremor [1]. Your UK prescriber will assess renal function through your medical history before prescribing either medication.

Pregnancy and breastfeeding considerations are similar for both antivirals. Aciclovir and valaciclovir are classified as pregnancy category B by regulatory bodies, with extensive safety data from pregnant women showing no increased risk of congenital abnormalities [3]. Both medications are considered compatible with breastfeeding, as only small amounts pass into breast milk. However, any prescription during pregnancy or lactation requires individual risk-benefit assessment by a UK prescriber.

Cost Comparison: Aciclovir vs Valaciclovir in the UK

Aciclovir has been available as a generic medication for over two decades, resulting in highly competitive pricing across UK pharmacies. At Cured Pharmacy, aciclovir cold sore treatment starts from £4.49, making it one of the most cost-effective antiviral options available. Topical aciclovir cream (Numark Cold Sore Cream) is available from £4.49 for patients who prefer localised treatment, though oral antivirals generally demonstrate superior efficacy for moderate to severe outbreaks.

Valaciclovir, whilst also available generically, typically costs more per treatment course than aciclovir across most UK pharmacies. However, the reduced pill burden (10 tablets vs 25 tablets for a five-day episodic course) may justify the price difference for patients who value convenience or struggle with frequent dosing schedules. Some patients find the total cost difference negligible when weighing adherence benefits.

For suppressive therapy, the monthly cost difference between aciclovir 400mg twice daily and valaciclovir 500mg once daily varies depending on the pharmacy and whether generic or branded versions are dispensed. Patients prescribed long-term suppression should discuss cost implications with their UK prescriber, as both regimens demonstrate similar efficacy in reducing recurrence frequency [4]. At Cured Pharmacy, our transparent upfront pricing shows exact costs before you complete your clinical consultation.

NHS Prescription vs Private Online Pharmacy

Both aciclovir and valaciclovir are available on NHS prescription for eligible patients, subject to standard prescription charges (currently £4.49 per item in England, free in Scotland, Wales, and Northern Ireland). Private online pharmacies like Cured Pharmacy offer an alternative for patients who prefer faster access, discreet packaging, or find it difficult to schedule GP appointments. All prescription medications dispensed through Cured Pharmacy require clinical assessment by UK-registered prescribers, ensuring the same safety standards as traditional NHS routes.

Choosing Between Aciclovir 400mg and Valaciclovir: Clinical Recommendations

For patients experiencing their first cold sore outbreak or infrequent recurrences (fewer than six episodes annually), aciclovir 400mg five times daily represents an effective and economical first-line choice. The dosing frequency, whilst demanding, is manageable for a five-day course, and the lower cost makes it accessible for episodic treatment. Patients who can maintain adherence to the five-times-daily schedule achieve excellent clinical outcomes comparable to valaciclovir.

Valaciclovir becomes particularly advantageous for patients with busy lifestyles, those who have previously struggled with aciclovir adherence, or individuals requiring long-term suppressive therapy. The twice-daily episodic regimen and once-daily suppressive option significantly reduce pill burden, potentially improving real-world effectiveness through better compliance. Some UK prescribers default to valaciclovir for professional patients (healthcare workers, teachers, customer-facing roles) where mid-day dosing presents practical challenges.

Patients with frequent recurrences (six or more episodes annually) should discuss suppressive therapy with their UK prescriber, regardless of which antiviral is chosen [4]. Continuous suppression reduces recurrence frequency by 70-80% on average and may improve quality of life more significantly than episodic treatment alone. Your Cured Pharmacy prescriber will assess your recurrence pattern, lifestyle factors, and treatment preferences to recommend the most appropriate option during your free online consultation.

When to Seek Specialist Review

Most cold sore cases respond well to either aciclovir or valaciclovir and can be managed through primary care or online pharmacy services. However, you should seek specialist review if lesions fail to heal within 10-14 days of treatment, recurrences become increasingly frequent despite suppressive therapy, or you develop severe systemic symptoms such as high fever or neurological changes. Immunocompromised patients (including those with HIV, organ transplant recipients, or individuals on immunosuppressive medications) require specialist oversight for herpes simplex management, as standard doses may be insufficient.

Scientific References

1. De Clercq, E., & Field, H. J. (2006). Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy. British Journal of Pharmacology, 147(1), 1–11. https://doi.org/10.1038/sj.bjp.0706446
2. Soul-Lawton, J., Seaber, E., On, N., Wootton, R., Rolan, P., & Posner, J. (1995). Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrobial Agents and Chemotherapy, 39(12), 2759–2764. https://doi.org/10.1128/AAC.39.12.2759
3. Spruance, S. L., Jones, T. M., Blatter, M. M., Vargas-Cortes, M., Barber, J., Hill, J., Goldstein, D., & Schultz, M. (2003). High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrobial Agents and Chemotherapy, 47(3), 1072–1080. https://doi.org/10.1128/AAC.47.3.1072-1080.2003
4. Chi, C. C., Wang, S. H., Delamere, F. M., Wojnarowska, F., Peters, M. C., & Kanjirath, P. P. (2015). Interventions for prevention of herpes simplex labialis (cold sores on the lips). Cochrane Database of Systematic Reviews, 2015(8), CD010095. https://doi.org/10.1002/14651858.CD010095.pub2
5. Claxton, A. J., Cramer, J., & Pierce, C. (2001). A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics, 23(8), 1296–1310. https://doi.org/10.1016/S0149-2918(01)80109-0

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.